Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 1 |
NetGPI | no | yes: 0, no: 1 |
Related structures:
AlphaFold database: A4HL87
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 2 |
GO:0016491 | oxidoreductase activity | 2 | 2 |
GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | 3 | 2 |
GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 4 | 2 |
GO:0047939 | L-glucuronate reductase activity | 5 | 2 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 7 | 9 | PF00675 | 0.742 |
CLV_PCSK_SKI1_1 | 128 | 132 | PF00082 | 0.667 |
CLV_PCSK_SKI1_1 | 74 | 78 | PF00082 | 0.630 |
DEG_Nend_UBRbox_3 | 1 | 3 | PF02207 | 0.713 |
DOC_CYCLIN_RxL_1 | 90 | 101 | PF00134 | 0.562 |
DOC_MAPK_gen_1 | 125 | 134 | PF00069 | 0.672 |
DOC_MAPK_gen_1 | 29 | 37 | PF00069 | 0.752 |
DOC_MAPK_gen_1 | 8 | 14 | PF00069 | 0.728 |
DOC_MAPK_MEF2A_6 | 125 | 134 | PF00069 | 0.672 |
DOC_PP1_RVXF_1 | 72 | 79 | PF00149 | 0.646 |
DOC_PP1_RVXF_1 | 91 | 98 | PF00149 | 0.314 |
DOC_USP7_UBL2_3 | 113 | 117 | PF12436 | 0.411 |
DOC_USP7_UBL2_3 | 99 | 103 | PF12436 | 0.652 |
LIG_14-3-3_CanoR_1 | 8 | 14 | PF00244 | 0.728 |
LIG_14-3-3_CanoR_1 | 93 | 98 | PF00244 | 0.651 |
LIG_APCC_ABBA_1 | 134 | 139 | PF00400 | 0.625 |
LIG_APCC_ABBA_1 | 146 | 151 | PF00400 | 0.535 |
LIG_BRCT_BRCA1_1 | 106 | 110 | PF00533 | 0.633 |
LIG_FHA_1 | 139 | 145 | PF00498 | 0.686 |
LIG_FHA_1 | 160 | 166 | PF00498 | 0.750 |
LIG_FHA_1 | 51 | 57 | PF00498 | 0.642 |
LIG_LIR_Gen_1 | 75 | 84 | PF02991 | 0.647 |
LIG_LIR_Nem_3 | 75 | 81 | PF02991 | 0.642 |
LIG_LYPXL_S_1 | 87 | 91 | PF13949 | 0.643 |
LIG_LYPXL_yS_3 | 88 | 91 | PF13949 | 0.646 |
LIG_PDZ_Class_1 | 163 | 168 | PF00595 | 0.753 |
LIG_Pex14_2 | 78 | 82 | PF04695 | 0.650 |
LIG_SH2_CRK | 84 | 88 | PF00017 | 0.652 |
LIG_SH2_NCK_1 | 45 | 49 | PF00017 | 0.666 |
LIG_SH2_SRC | 45 | 48 | PF00017 | 0.666 |
LIG_SH2_STAP1 | 119 | 123 | PF00017 | 0.679 |
LIG_SH2_STAP1 | 45 | 49 | PF00017 | 0.666 |
LIG_SH3_3 | 54 | 60 | PF00018 | 0.657 |
LIG_UBA3_1 | 91 | 99 | PF00899 | 0.649 |
LIG_WRC_WIRS_1 | 94 | 99 | PF05994 | 0.564 |
MOD_GlcNHglycan | 106 | 109 | PF01048 | 0.592 |
MOD_GlcNHglycan | 165 | 168 | PF01048 | 0.755 |
MOD_GSK3_1 | 153 | 160 | PF00069 | 0.736 |
MOD_LATS_1 | 157 | 163 | PF00433 | 0.750 |
MOD_NEK2_1 | 112 | 117 | PF00069 | 0.579 |
MOD_PK_1 | 31 | 37 | PF00069 | 0.762 |
MOD_PKA_2 | 153 | 159 | PF00069 | 0.734 |
MOD_PKA_2 | 7 | 13 | PF00069 | 0.730 |
MOD_Plk_1 | 74 | 80 | PF00069 | 0.638 |
MOD_Plk_4 | 77 | 83 | PF00069 | 0.650 |
MOD_SUMO_rev_2 | 120 | 130 | PF00179 | 0.680 |
MOD_SUMO_rev_2 | 3 | 10 | PF00179 | 0.727 |
MOD_SUMO_rev_2 | 96 | 105 | PF00179 | 0.653 |
TRG_DiLeu_BaLyEn_6 | 101 | 106 | PF01217 | 0.455 |
TRG_DiLeu_BaLyEn_6 | 90 | 95 | PF01217 | 0.643 |
TRG_ENDOCYTIC_2 | 84 | 87 | PF00928 | 0.652 |
TRG_ENDOCYTIC_2 | 88 | 91 | PF00928 | 0.576 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A2QAC0 | ASPNC | 27% | 44% |
P07846 | SHEEP | 33% | 47% |
P0DMQ6 | CHICK | 33% | 47% |
P27867 | RAT | 34% | 47% |
P36624 | SCHPO | 34% | 47% |
P77280 | ECOLI | 36% | 48% |
Q06004 | BACSU | 31% | 48% |
Q07993 | YEAST | 38% | 47% |
Q1PSI9 | VITVI | 32% | 46% |
Q58D31 | BOVIN | 33% | 47% |
Q59545 | MORMO | 69% | 50% |
Q5R5F3 | PONAB | 35% | 47% |
Q64442 | MOUSE | 36% | 47% |
Q7SI09 | NEUCR | 30% | 46% |
Q8U7Y1 | AGRFC | 45% | 48% |
Q92MT4 | RHIME | 60% | 49% |
Q96V44 | HYPJE | 29% | 45% |
Q98D10 | RHILO | 48% | 48% |